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Abstract
We previously reported that the G allele of rs3853839 at 39untranslated region (UTR) of Toll-like receptor 7 (TLR7) was
associated with elevated transcript expression and increased risk for systemic lupus erythematosus (SLE) in 9,274 Eastern
Asians [P= 6.5610210, odds ratio (OR) (95%CI) = 1.27 (1.17–1.36)]. Here, we conducted trans-ancestral fine-mapping in
13,339 subjects including European Americans, African Americans, and Amerindian/Hispanics and confirmed rs3853839 as
the only variant within the TLR7-TLR8 region exhibiting consistent and independent association with SLE (Pmeta = 7.5610
211,
OR = 1.24 [1.18–1.34]). The risk G allele was associated with significantly increased levels of TLR7 mRNA and protein in
peripheral blood mononuclear cells (PBMCs) and elevated luciferase activity of reporter gene in transfected cells. TLR7 39UTR
sequence bearing the non-risk C allele of rs3853839 matches a predicted binding site of microRNA-3148 (miR-3148),
suggesting that this microRNA may regulate TLR7 expression. Indeed, miR-3148 levels were inversely correlated with TLR7
transcript levels in PBMCs from SLE patients and controls (R2 = 0.255, P= 0.001). Overexpression of miR-3148 in HEK-293 cells
led to significant dose-dependent decrease in luciferase activity for construct driven by TLR7 39UTR segment bearing the C
allele (P= 0.0003). Compared with the G-allele construct, the C-allele construct showed greater than two-fold reduction of
luciferase activity in the presence of miR-3148. Reduced modulation by miR-3148 conferred slower degradation of the risk
G-allele containing TLR7 transcripts, resulting in elevated levels of gene products. These data establish rs3853839 of TLR7 as
a shared risk variant of SLE in 22,613 subjects of Asian, EA, AA, and Amerindian/Hispanic ancestries (Pmeta= 2.0610
219,
OR = 1.25 [1.20–1.32]), which confers allelic effect on transcript turnover via differential binding to the epigenetic factor miR-
3148.
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Introduction
Systemic lupus erythematosus (SLE [OMIM 152700]) is a
complex and heterogeneous autoimmune disease with a strong
genetic component that is modified by environmental exposures.
Although the detailed etiopathogenesis of SLE remains unknown,
excessive innate immune activation involving toll-like receptors
(TLRs, particularly TLR7/8/9) and type I interferon (IFN) has
been recognized as an important pathogenic mechanism in the
disease [1]. Therapeutics targeting the TLR/IFN pathway are in
development for the treatment of SLE, with ongoing clinical trials
investigating monoclonal antibodies against IFN-a and inhibitors
for TLR7/TLR9 (reviewed in [2]). Recent genome-wide associ-
ation (GWA) and follow-up studies have revealed the association of
a number of polymorphic variants in genes encoding components
of the TLR/type I IFN pathway with susceptibility to SLE
(reviewed in [3,4]), providing insights at the molecular level to
refine our understanding of this dysregulated pathway in the
predisposition to SLE.
Our previous study identified a single nucleotide polymorphism
(SNP), rs3853839, in the 39 UTR of an X-linked gene TLR7 to be
associated with SLE in 4,334 cases and 4,940 controls of Eastern
Asian descent [5], providing the first convincing evidence for the
genetic contribution of TLR7 to human SLE. Individuals carrying
the risk G allele exhibited increased TLR7 transcripts and a more
robust IFN signature than non-risk C allele carriers [5]. In this
study, by fine mapping the TLR7-TLR8 region, we confirmed that
the previously reported functional SNP rs3853839, located within
a predicted binding site of miR-3148, was most likely responsible
for observed association with SLE in three populations of non-
Asian ancestry. We demonstrated a differential miR-3148
modulation explaining the effect of allelic variation at rs3853839
on TLR7 expression.
Results
Confirmation of the association between rs3853839 and
SLE susceptibility in European American, African
American, and Hispanic ancestries
We conducted genotyping and imputation for genetic variants
covering ,80 kb of the TLR7-TLR8 region on Xp22.2. After
applying quality control measures, 41 genotyped SNPs and 57–75
imputed SNPs/INDELs (insertion-deletion) (varying among dif-
ferent ancestries) were assessed for association with SLE in
unrelated cases and healthy controls of European American (EA,
3,936 cases vs. 3,491 controls), African American (AA, 1,679 vs.
1,934) and Hispanic enriched for the Amerindian-European
admixture (HS, 1,492 vs. 807) descent (Figure 1A).
The strongest association signal was consistently detected at
rs3853839 in the three ancestries, including EA (minor allele
frequency of 20.3% in cases vs. 17.2% in controls, P= 6.561026,
OR [95%CI] = 1.23 [1.13–1.35]), AA (19.8% vs. 16.7%,
P= 1.161023, OR = 1.24 [1.09–1.41]) and HS (44.8% vs.
37.3%, P= 7.561024, OR = 1.26 [1.10–1.43]) (Figure 1B,
Table 1). After Bonferroni correction for multiple comparisons,
the association of rs3853839 with SLE remained significant in EA
and HS, and reached a nominal significance in AA. Combining
the EA, AA and HS datasets, the meta-analysis P value of
rs3853839 (Pmeta = 7.5610
211, OR = 1.24 [1.18–1.34]) exceeded
the commonly used threshold of 561028 for genome-wide
significance (Figure 1C, Table 1). Thus, the association of
rs3853839 with SLE previously identified in Eastern Asians was
confirmed in three non-Asian ancestries.
Only six other SNPs within a relatively small interval of 5 kb
spanning from TLR7 39downstream to TLR8 intron 1 were
consistently associated with SLE (P,0.05) in EA, AA and HS
(Table S1), and remained significant trans-ancestral meta-analysis
P values after Bonferroni correction (5.561026#Pmeta#1.3610
26,
Table S1). Linkage disequilibrium (LD) analysis revealed low LD
strength between rs3853839 and these SNPs across non-Asian
ancestries (r2,0.26, 0.37, and 0.51 in EA, AA and HS,
respectively), but these 6 SNPs are in strong LD with each other
and could be defined as a block (Figure S1). Among them, non-
synonymous SNP rs3764880 (Met1Val) located at TLR8 exon1
exhibited the strongest association (Pmeta = 1.3610
26, OR = 1.15;
Table S1). To distinguish whether the associations of these 6 SNPs
with SLE were independent of rs3853839, we performed
conditional haplotype-based association test. After conditioning
on rs3853839, association signals detected at these 6 loci were
completely eliminated in EA, AA and HS (Figure S1). In contrast,
conditioning on rs3764880, a consistent association signal was
detected at rs3853839 in EA and HS (Figure S1), indicating that
the association signals detected at these 6 SNPs might be
attributed to that of rs3853839.
MiR-3148 Modulates SLE–Associated TLR7 SNP
PLOS Genetics | www.plosgenetics.org 2 February 2013 | Volume 9 | Issue 2 | e1003336
Taken together, we confirmed rs3853839 as the only SNP in the
TLR7-TLR8 region showing an independent association with SLE
across all three non-Asian ancestries. A meta-analysis by
combining all datasets of Asian and non-Asian ancestries showed
compelling evidence of association with SLE at rs3853839
(Pmeta = 2.0610
219, OR = 1.25 [1.20–1.32], Table 1). Given the
location of TLR7 at X chromosome, we examined the allelic
association of rs3853839 separately by gender. Of note, the sex-
specific association of rs3853839 with SLE previously detected in
Asian men [5] was not replicated in non-Asian ancestries (Table 1).
Regulation of TLR7 expression by rs3853839
Given the convincing evidence for the trans-ancestral associa-
tion of rs3853839 with SLE susceptibility, we then evaluated its
effect on regulation of TLR7/8 expression. Messenger RNA
(mRNA) levels of TLR7 and the two alternative TLR8 isoforms
were measured by real-time PCR in PBMCs from healthy EA
individuals (n = 62). TLR7 mRNA levels were significantly
different among women (n = 41) carrying different genotypes of
rs3853839 [P= 0.003, one-way analysis of variance (ANOVA)], in
which the GG and GC carriers exhibited notably increased TLR7
mRNA levels compared with the CC carriers [P= 0.02 for GG
(n = 5) vs. CC (n = 18) and 0.02 for GC (n = 18) vs. CC,
respectively, Student’s t test; Figure 2A) and the number of
rs3853839 risk G allele was significantly correlated with increased
TLR7 mRNA levels (R2 = 0.26, P= 861024, linear regression test).
Consistently, male G allele carriers (n = 5) also had significantly
higher TLR7 mRNA expression than male C allele carriers
(n = 16) (P= 0.01, Figure 2A). There was no significant association
of rs3853839 genotypes with mRNA levels of two TLR8 isoforms
in either women or men (Figure 2A). No sex differences in TLR7
or TLR8 mRNA levels were observed between individuals carrying
the same genotype [GG women vs. G men: P= 0.41 (TLR7), 0.63
(TLR8a) and 0.50 (TLR8b); CC women vs. C men: P= 0.10
(TLR7), 0.91 (TLR8a) and 0.65 (TLR8b)]. These results were in
accordance with our previous observations in Chinese [5],
supporting the importance of rs3853839 in regulating TLR7
rather than TLR8 gene expression.
We assessed the intracellular expression of TLR7 and TLR8
proteins by flow cytometry in PBMCs from 7 pairs of healthy women
(GG vs. CC) and men (G vs. C), respectively. Of the 7 pairs of
individuals in each gender, 4 pairs were of EA descent and 3 pairs were
Asians. Compared with C allele carriers, G allele carriers had
significantly higher TLR7 protein levels in PBMCs (P= 0.038 and
0.009 in women and men, respectively; Figure 2B), especially in CD19+
B cells and CD14+ monocytes (Figure S2). No significant association
between rs3853839 genotypes and TLR8 protein levels was observed
in either total PBMCs or in specific cell subsets (Figure S3).
We next performed luciferase reporter assays to further confirm
the functional effect of rs3853839 on TLR7 expression. PCR-
amplified TLR7 39UTR fragments with either the G or C allele of
rs3853839 were cloned downstream of an SV40 promoter-driven
Renilla luciferase gene in the psiCHECK-2 vector, which also
contained a firefly luciferase gene to serve as an internal
transfection normalization control (Figure 2C). Constructs were
then transiently transfected into either HEK-293 or differentiated
HL-60 (dHL-60, neutrophil-like cells) cells. After 24 hours, cell
lysates transfected with the G-allele construct showed significantly
higher luciferase activity than those transfected with the C-allele
construct in both HEK-293 and dHL-60 cells (P= 0.026 and
0.009, respectively; Figure 2C). Taken together, consistent results
from ex vivo and in vitro studies indicated that the SLE-risk G allele
of rs3853839 conferred elevated TLR7 expression at the both
mRNA and protein level.
Allelic differences of rs3853839 in TLR7 mRNA
degradation rate
To explore the mechanism of rs3853839 in regulating TLR7
mRNA turnover, we assessed allelic difference in TLR7 mRNA
degradation by pyrosequencing. We first determined the
rs3853839 G/C allele ratio in genomic DNA (gDNA) and cDNA
from healthy EA women (n = 7) carrying the GC genotype. The
mean G/C allele ratio in cDNA was significantly higher than the
theoretical ratio of 1 as detected in gDNAs (P= 0.02, Figure S4),
indicating a higher expression of the G- than the C-allele
containing TLR7 transcripts in heterozygous PBMCs. The allelic
specific expression analysis in EA was similar to our previous
findings in Chinese [5], and confirmed the result of real-time PCR
that the G allele of rs3853839 is associated with increased TLR7
mRNA expression. Then, PBMCs were cultured in the absence or
presence of the transcriptional inhibitor actinomycin D (ActD),
and the G/C allele ratio in cDNA (normalized to that measured in
gDNA) was determined after 0, 2, 4, 6, and 24 hours, respectively.
As shown in Figure 2D and 2E, the G/C ratio in cDNA appeared
to change over time when PBMCs were incubated with ActD and
exhibited a statistical difference at the 4 hour point (P= 0.04),
implicating slower degradation of the G allele- than the C allele-
containing TLR7 transcript in heterozygous PBMCs. The
inhibitory effect of ActD on RNA synthesis was corroborated by
a decrease in total TLR7 mRNA level at increasing time points
after the addition of ActD in PBMC aliquots measured by real-
time PCR (Figure S5).
Alteration of microRNA–3148–mediated modulation of
TLR7 expression by rs3853839
MicroRNAs (miRNAs) that bind to target sequences located
within the 39UTR of mRNAs by base pairing have been shown to
result in accelerated mRNA turnover or translation repression [6].
Author Summary
Systemic lupus erythematosus (SLE) is a debilitating
autoimmune disease contributed to by excessive innate
immune activation involving toll-like receptors (TLRs,
particularly TLR7/8/9) and type I interferon (IFN) signaling
pathways. TLR7 responds against RNA–containing nuclear
antigens and activates IFN-a pathway, playing a pivotal
role in the development of SLE. While a genomic
duplication of Tlr7 promotes lupus-like disease in the Y-
linked autoimmune accelerator (Yaa) murine model, the
lack of common copy number variations at TLR7 in humans
led us to identify a functional single nucleotide polymor-
phism (SNP), rs3853839 at 39 UTR of the TLR7 gene,
associated with SLE susceptibility in Eastern Asians. In this
study, we fine-mapped the TLR7-TLR8 region and con-
firmed rs3853839 exhibiting the strongest association with
SLE in European Americans, African Americans, and
Amerindian/Hispanics. Individuals carrying the risk G allele
of rs3853839 exhibited increased TLR7 expression at the
both mRNA and protein level and decreased transcript
degradation. MicroRNA-3148 (miR-3148) downregulated
the expression of non-risk allele (C) containing transcripts
preferentially, suggesting a likely mechanism for increased
TLR7 levels in risk-allele carriers. This trans-ancestral
mapping provides evidence for the global association
with SLE risk at rs3853839, which resides in a microRNA–
gene regulatory site affecting TLR7 expression.
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Table 1. Association of rs3853839 with SLE in multiple ancestries.
Frequency Trans-ethnic meta analysis
Sex Ethnicity Case/Control
Test
Allele Case Control P OR (95%CI) Pmeta OR (95%CI)
All EA 3,936/3,491 G 20.3% 17.2% 6.5E-06 1.23 (1.13–1.35)
AA 1,679/1,934 G 19.8% 16.7% 1.1E-03 1.24 (1.09–1.41)
HS 1,492/807 G 44.8% 37.3% 7.5E-04 1.26 (1.10–1.43)
AS* 4,334/4,940 G 81.0% 77.0% 6.5E-10 1.27 (1.17–1.36)
Combined EA+AA+HS 7.5E-11 1.24 (1.18–1.34)
Combined EA+AA+HS+AS 2.0E-19 1.25 (1.20–1.32)
Female EA 3,592/2,340 G 20.3% 16.5% 1.9E-06 1.26 (1.15–1.39)
AA 1,543/1,342 G 19.7% 16.6% 3.4E-03 1.22 (1.07–1.40)
HS 1,365/727 G 44.9% 36.7% 2.5E-04 1.29 (1.13–1.48)
AS* 3,976/3,390 G 80.0% 77.0% 1.2E-07 1.24 (1.14–1.34)
Male EA 344/1,151 G 19.9% 20.0% 0.9 0.98 (0.73–1.33)
AA 136/592 G 22.8% 16.8% 0.1 1.46 (0.93–2.30)
HS 127/80 G 43.4% 49.4% 0.3 0.75 (0.42–1.34)
AS* 358/1,550 G 89.0% 77.0% 1.3E-06 2.33 (1.64–3.30)
*AS: Previously published data in population of Eastern Asian descent (5).
Abbreviation: AS, Eastern Asian; AA, African American; EA, European American; HS, Amerindian/Hispanics; OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pgen.1003336.t001
Figure 1. Allelic associations of SNPs in the TLR7-TLR8 region with SLE. (A) The genomic structure of the TLR7-TLR8 region and the location of
all studied SNPs are indicated. (B) Association signals (2log10P) are plotted against the position of each SNP (based on GRch37/hg19) in European
Americans (EA), African Americans (AA), and Hispanics (HS). Genotyped and imputed SNPs are depicted with circles and triangles, respectively. The
diamond identifies the TLR7 39UTR SNP rs3853839. SNPs are highlighted using different colors according to their LD strength (r2) with rs3853839. (C) A
trans-ancestral meta-analysis is conducted on 40 genotyped SNPs (circles) and 14 imputed SNPs (triangles) that are shared by the three ancestries
(SNPs listed in Table S1) using fixed and random model, respectively. The dashed line represents the significance level of 561028.
doi:10.1371/journal.pgen.1003336.g001
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Single nucleotide change either within or around the sequence of
miRNA target sites can potentially alter the base-pairing patterns
and affect miRNA-mediated regulation [7,8]. The updated
TargetScan database (Release 6.2; http://www.targetscan.org)
indicates that rs3853839 is located within a binding site of miR-
3148, where the non-risk allele (C), but not the risk allele (G), is
predicted to match miR-3148 at the second position (Figure 3A).
We hypothesized that the C to G variation of rs3853839 could
reduce the binding and regulation incurred by miR-3148,
therefore, leading to dysregulated TLR7 expression. We first
showed that transcript levels of miR-3148 and TLR7 were
inversely correlated in PBMCs from 16 patients with SLE and
21 healthy controls (R2 = 0.255, P= 0.001; Figure 3B), suggesting the
possible regulation of TLR7 expression by miR-3148. Next, to verify
whether allelic variation of rs3853839 affects the interaction of miR-
3148 with TLR7 39UTR, psiCHECK-2 vectors containing TLR7
39UTR segment with either the C or G allele of rs3853839 were
cotransfected with various doses of miR-3148 or nontarget control
mimic into HEK-293 cells. As shown in Figure 3C, we observed
significant dose-dependent miR-3148-mediated decrease in luciferase
activity for the C-allele construct (P= 0.0003 over all miR-3148-
treated C-allele vector groups, ANOVA test), but not for the G-allele
construct (P= 0.14). Cotransfection with miR-3148 at a concentra-
tion of 6, 12, and 48 nM, respectively, led to greater than two-fold
Figure 2. The SLE-risk G allele of rs3853839 confers elevated TLR7 expression through slower mRNA degradation. (A) Association of
rs3853839 genotypes with TLR7/8 transcript levels in EA normal PBMCs. Each symbol represents an individual and horizontal lines indicate mean 6
SEM values. (B) Association of rs3853839 genotypes with TLR7 protein levels in normal PBMCs. FACS histograms show the log MFI values plotted
against the cell counts for PBMCs in individuals carrying G or C allele, compared with isotype control. Results are from one representative pair (GG or
G vs. CC or C) of 7 in each gender group. MFI of TLR7 expression in PBMCs is graphically depicted. Each symbol represents an individual and
horizontal lines indicate mean6 SEM values. (C) Verification of the G allele conferring elevated expression of a luciferase reporter in vitro. TLR7 39UTR
segment bearing G or C allele of rs3853839 was cloned into the psiCHECK-2 reporter vector and luciferase activity was determined after 24 hours of
transfection. Relative luciferase activity is Renilla/Firefly luciferase ratio. Data show the mean 6 SEM and are representative of cumulative data from
four independent experiments. (D) The kinetics of the G/C allele ratio in TLR7 transcripts from PBMCs of healthy heterozygous individuals (n = 7) in the
absence or presence of actinomycin D (ActD). The G/C allele ratio obtained in TLR7 transcripts was normalized to that measured from gDNA of the
same sample. Data are expressed as mean 6 SEM at each time point and representative of cumulative data from two independent experiments with
seven healthy donors. *P,0.05. (E) Summary of the G/C allele ratio in TLR7 transcripts 4 hours after the addition of ActD or vehicle control (n = 7).
Comparisons are between ActD and vehicle control cultures; P= 0.04; paired t test. FACS, Fluorescence-activated cell sorter; MFI, mean fluorescence
intensity.
doi:10.1371/journal.pgen.1003336.g002
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reduction of luciferase activity in the C-allele than the G-allele
construct [reduction in C-allele vs. G-allele construct: 13.2% vs.
4.8%, P= 0.023 (6 nM); 22.5% vs. 9.9%, P= 0.0012 (12 nM); 21.4%
vs. 8.5%, P= 0.0031 (48 nM)]. These data supported the bioinfor-
matic prediction that miR-3148 directly targets TLR7 39UTR and
the C to G variation of rs3853839 within the binding site alters the
inhibitory effect of miR-3148 on modulating TLR7 expression.
Discussion
Fine-mapping of the TLR7-TLR8 region with high-density
genetic markers based on large scale genotyping and imputation
confirmed SNP rs3853839 at TLR7 39UTR as the most likely
causal variant responsible for the association of TLR7-TLR8
region with SLE in populations of EA, AA and HS ancestry. In
accordance with our previous observation in Asians [5], we
detected elevated TLR7 expression at both mRNA and protein
levels in PBMCs from EA homozygous risk G allele carriers, as
well as a higher level of the risk than the non-risk allele-containing
TLR7 transcripts in EA heterozygous PBMCs. The fact that two
distinct ancestries share the same genotype-phenotype association
implicates an important regulatory effect of rs3853839 on TLR7
expression. Toward this end, we have extended functional studies
showing slower degradation of the risk allele-containing TLR7
transcripts in heterozygous PBMCs and regulation of TLR7
expression by miRNA-3148 that targets 39UTR at the position of
rs3853839. Finally, we showed that the presence of the risk G
allele resulted in reduced suppression by miRNA-3148, suggesting
a likely mechanism for increased TLR7 expression in risk-allele
carriers.
The importance of TLR7 upregulation on mediating autoim-
mune responses has been addressed in murine models of SLE. The
Y-linked autoimmune accelerator (Yaa) modifier, suggested mainly
due to Tlr7 gene duplication, provides a prime example of TLR7
dysregulation leading to autoreactivity and inflammatory pathol-
ogy [9–11]. Increasing Tlr7 gene dosage via generation of
transgenic mice results in development of systemic autoimmunity,
the severity of which directly correlates with the degree of Tlr7
overexpression [12]. Increased Tlr7 gene dosage promotes
autoreactive lymphocytes activation, dendritic cells proliferation,
and secretion of proinflammatory cytokines and IFN-a [12], which
in turn upregulates TLR7 expression, leading to a feedback loop
exacerbating autoimmunity [13]. In patients affected with SLE,
up-regulated expression of TLR7 mRNA has been reported in
PBMCs and B cells [14,15]. Although a copy number variation
(CNV) study in Mexican population showed increased TLR7
Figure 3. The SLE-risk G allele of rs3853839 displays reduced transcript modulation by miR-3148. (A) TargetScan’s predicted miR-3148-
binding site in TLR7 39UTR. The C allele, rather than G allele of rs3853839 corresponds to the second base of this seed region. (B) Inverse correlation of
miR-3148 and TLR7 transcript levels in PBMCs from 16 patients with SLE (solid circles) and 21 controls (open diamonds). (C) HEK-293 cells were
cotransfected with empty reporter vector (EV), luciferase constructs driven by TLR7 39UTR segment containing either C or G allele of rs3853839 and
increasing concentrations (1, 6, 12, and 48 nM) of miR-3148 or nontarget control (NC) mimics. Luciferase activity was determined 24 hours after
transfection. Normalized luciferase activity is the Renilla/Firefly ratio of miR-3148-treated reporter vector compared with the same NC-treated reporter
vector. Data show the mean 6 SEM and are representative of cumulative data from three independent experiments. P= 0.0003 over all miR-3148-
treated C-allele vector groups, and not significant over all miR-3148-treated G-allele or empty vector groups (ANOVA test). P*= 0.02, P**,0.0001
(Student’s t test) for the comparison of indicated groups.
doi:10.1371/journal.pgen.1003336.g003
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copies in childhood-onset SLE patients [16], no evidence for
common CNVs at the TLR7-TLR8 region has been identified in
individuals of diverse ancestries through our previous study by
three independent methods including quantitative real-time PCR,
PmeI pulsed-field gel electrophoresis and Southern blot [5], two
recent studies using customized CGH platforms [17,18] as well as
other studies listed in the Database of Genomic Variants (http://
projects.tcag.ca/variation; the latest version released in November
2010), suggesting that mutations similar to Yaa are not a frequent
feature of human SLE. The current study identifying genetic
variations conferred by a regulatory SNP in TLR7 expression and
SLE susceptibility suggests that murine models provide profound
clues to human genetics if we look beyond the specific mutations
identified in the relevant pathways.
Unlike our findings in Asians that both sexes showed association
[5], the impact of rs3853839 on risk for SLE was only observed for
women in the non-Asian datasets (Table 1). Given the low
prevalence of SLE in men, it is often challenging to collect a large
enough number of affected men in a given population. Under the
assumption that the associated G allele confers genetic risk with an
odds ratio of 1.26 in EA, 1.22 in AA and 1.29 in HS subjects (ORs
were determined in female datasets), and considering P,0.05 as
the threshold of significance, the power estimate for female
samples in each ancestry reaches more than 85%, whereas for
male samples it is only 50% in EA, 19% in AA and 25% in HS
dataset. Thus, there was clearly inadequate power to evaluate this
association in AA and HS men. Despite a relatively robust sample
size of EA men (344 SLE vs. 1,151 controls), a significantly higher
G allele frequency was observed in male than female controls
(20.0% vs. 16.5%, P= 0.005), contributing to the difficulty in
assessing association with SLE in EA male subjects.
To our knowledge, the association of rs3853839 (or its tag SNP)
with SLE has not been reported in four SLE GWA studies in
European-derived populations [19–22] and three GWA studies in
Asians [23–25]. According to the 1000 Genomes Project data,
rs3853839 locates in a region with poor LD structure and cannot
be tagged by any known SNP at the TLR7-TLR8 region with
r2.0.65. The SNP rs850632, located at TLR7 39downstream,
shows the strongest LD with rs3853839 in Europeans (r2 = 0.38)
and Asians (r2 = 0.65). However, neither rs3853839 nor rs850632
has been included in predesigned commercial genotyping arrays of
those GWA studies, resulting in the absence of associations. Even
if rs3853839 was genotyped, the published GWA studies might
have inadequate statistical power to capture its association in the
initial discovery analyses [5].
Evidence of other TLR7 polymorphisms associated with SLE
has been reported, including two intronic SNPs (rs179019 and
rs179010) found in Japanese population [26] and an exonic SNP
(rs179008) in individuals from Southern Brazil [27]. The reported
associations were modest due to limited sample size of these studies
(less than 400 cases and 450 controls), and none of them have been
confirmed by the current fine-mapping study using a large
collection of EA, AA and HS cases-controls (Table S1). TLR8
polymorphisms have been described in infectious diseases [28,29]
with a genetic effect localized to a functional variant at exon 1
(rs3764880, Met1Val). The G allele of rs3764880, which abolishes
a putative start codon within the alternative TLR8 transcript
isoform a (Figure 1A), conferred a protective effect on suscepti-
bility to pulmonary tuberculosis in Indonesian and Russian men
[28], as well as on HIV disease progression in Germans [29]. Our
data showed a significantly increased frequency of rs3764880-G
allele in SLE than healthy controls in the three non-Asian datasets;
however, its association with SLE was dependent on that of TLR7
SNP rs3853839. Other variants at the TLR7-TLR8 region showed
either weaker association than rs3853839 in trans-ancestral meta-
analysis or association uniquely in EA or HS. Taken together,
these data support rs3853839 as the most likely polymorphism
associated with SLE shared by multiple ancestries. Although
imputation facilitated our ability to capture common variants
(MAF.1%), further refinement in genetic effects of rare variants
(MAF,1%) is needed by deep sequencing of this locus, especially
the intergenic region between TLR7 and TLR8 that was not well
imputed in this study.
Variations in 39UTR regions may be important in gene
regulation. To date, expression quantitative trait loci (eQTL)
mapping has been widely used for characterization of SNPs that
affect gene expression [30]. Although the TLR7 expression has
been measured in previous whole-genome eQTL studies, currently
only those using EBV-transformed lymphoblastoid cell lines of
1000 Genomes Project individuals provide publically available
genotyping data of rs3853839. Based on the study by Stranger et al
[31], we found that CG carriers of rs3853839 showed elevated
TLR7 expression compared with CC carriers in YRI women
(P= 0.012). In male individuals, the G allele of rs3853839 showed
a trend of association with elevated TLR7 expression in
CHB+JPT, CEU and YRI men, and the association was
significant when combining all male data (P= 0.014). These
findings are consistent with our results that rs3853839 alleles are
associated with differential TLR7 expression.
An important finding of this study is that the SLE-associated
variant rs3853839 confers a genetic effect on modulation of TLR7
expression by an epigenetic factor miR-3148. Accumulating
evidence suggests that miRNAs are fine tuners of TLR signaling
pathways [32]. Regulation by miRNA may occur at various levels
of TLR pathways by targeting adaptor molecules, downstream
regulators and cytokines (reviewed in [32,33]). However, few
studies point to TLR themselves (e.g. TLR2 and TLR4) being
directly targeted by miRNAs [34,35]. Using algorithms from
TargetScan, only the newly identified human miR-3148 [36],
which is not evolutionarily conserved among mammals, is
predicted to bind TLR7 39UTR sequences at the position of
rs3853839. The inverse correlation of miR-3148 and TLR7 levels
in PBMCs, along with functional validation by reporter gene
assay, confirms an inhibitory effect of miR-3148 on regulating
TLR7 expression and allelic variation of rs3853839 affecting
miRNA-mRNA interactions. Further study will focus on investi-
gating miR-3148 expression patterns in specific immune cell types,
assessing biological impacts of changes in miR3148-mediated
TLR7 expression on downstream immune responses, and
evaluating roles of other miRNAs that target sequences in the
vicinity of rs3853839. Of interest, an unconventional role for
miRNAs has been identified as endogenous activators for RNA-
sensing receptors (TLR7/8) in a cell- or tissue-type specific
manner [37,38]. Therefore, miRNA regulation in TLR7 signaling
is more complicated than we expected and further functional
studies showing the exact effects of miRNAs on TLR7 responses
are warranted.
In summary, we have advanced our previous study by showing
rs3853839 (at TLR7 39UTR) as the most likely polymorphism
responsible for the association of TLR7-TLR8 region with SLE in
individuals of EA, AA and HS ancestry, and have characterized a
differential miR-3148 modulation which explains the effect of
allelic variation of rs3853839 on TLR7 expression. Our study
highlights the importance of TLR7 as a shared genetic contributor
to SLE in multiple ancestries, and provides evidence that
microRNA acts as a negative regulator to control TLR7
expression, suggesting the possibility of miRNA-based therapies
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for amelioration of autoimmune diseases such as SLE where
excessive TLR7 activation exists.
Materials and Methods
Ethics statement
Written informed consent was obtained from all study
participants and each participating institution had Institutional
Review Board (IRB) approval to recruit samples. The overall study
was approved by the IRB of the Oklahoma Medical Research
Foundation (OMRF).
Subjects
To test the association of TLR7-TLR8 with SLE, we used a large
collection of case-control subjects from the collaborative Large
Lupus Association Study 2 (LLAS2), including European American
(4,248 cases vs. 3,818 controls), African American (1,724 cases vs.
2,024 controls), and Hispanic enriched for the Amerindian-
European admixture (1,622 cases vs. 887 controls). African
Americans included 286 Gullahs (155 cases vs. 131 controls), who
are subjects with African ancestry. Cases were defined by meeting at
least four of the 1997 American College of Rheumatology (ACR)
revised criteria for the classification of SLE [39].
SNP genotyping and quality control
DNA samples were processed at the Lupus Genetics Studies
Unit of OMRF. SNP genotyping was performed using an Illumina
custom bead array on the iSCAN instrument for 47 SNPs covering
the TLR7-TLR8 region on Xp22.2 and 347 admixture informative
markers (AIMs). SNPs meeting the following criteria were
included in the association analysis: well-defined cluster scatter
plots, SNP call rate .90%, minor allele frequency .1%, total
proportion missing ,5%, P.0.05 for differential missing rate
between cases and controls, and Hardy-Weinberg proportion
(HWP) test with a P.0.01 in controls and P.0.0001 in cases.
Subjects with genotype missing rate .10% (due to low quality),
shared identical by descent .0.4 or showing mismatch between
the reported and estimated gender were removed. The global
ancestry of each subject was estimated based on genotype of AIMs
using principal components analysis [40] and ADMIXMAP [41],
as described in another LLAS2 study [42], and then genetic
outliers were removed.
Finally, a total of 13,339 unrelated subjects, including European
Americans (EA: 3,936 cases vs. 3,491 controls), African Americans
(AA: 1,679 vs. 1,934; composed of 92.5% of African Americans
and 7.5% Gullahs) and Hispanics enriched for the Amerindian-
European admixture (HS: 1,492 vs. 807), were analyzed for 41
genotyped SNPs of TLR7-TLR8.
Imputation methods
Imputation was performed at 12.86–12.95 Mb on Xp22.2 using
IMPUTE 2.1.2 [43], with SNP/INDEL genotypes of 381
Europeans, 246 Africans and 181 Americans from the 1000
Genomes Project (‘‘version 3’’ of the Phase 1 integrated data,
March 2012 release) as references in imputation for our EA, AA
and HS subjects, respectively. Imputed genotypes had to meet
information score of .0.9, as well as the quality control criteria as
described above. After imputation, we obtained an additional 75
variants for EA, 57 for AA and 63 for HS (the number varied
based on LD structure) for further analysis.
Real-time PCR
Total RNA was purified with TRIzol reagent (Invitrogen) from
PBMCs and reverse-transcribed into cDNA with Superscript II
Reverse Transcription kit (Invitrogen). The mRNA levels of TLR7
(NM016562.3) and TLR8 (isoform a: NM138636.4 and isoform b:
AF246971.1) were measured by quantitative real-time PCR using
TaqMan assays (TLR7 probe: Hs00152971_m1; TLR8 isoform a
probe: Hs00607866_mH; TLR8 isoform b probe: Hs00152972_ml,
Applied Biosystems). All samples were run in triplicate. Relative
expression levels of TLR7 and TLR8 were normalized to the level of
RPLP0, calculated by the 22DDCt method and Log10 transformed.
The association of rs3853839 with mRNA levels of TLR7 or TLR8
was evaluated using ANOVA, Student’s t and linear regression test.
To examine the correlation of miR-3148 and TLR7 mRNA
levels, total RNA enriched in small RNAs were isolated from
PBMCs using mirVanaTM miRNA isolation kit (Invitrogen),
followed by reverse transcription with TaqMan MicroRNA
Reverse Transcription kit (Applied Biosystems; for detecting
miR-3148) and Superscript II Reverse Transcription kit (Invitro-
gen; for detecting TLR7), respectively. The miR-3148 level was
quantified using Taqman MicroRNA Expression assay (Applied
Biosystems), and the TLR7 level was measured using the same
probe as described above. All samples were run in triplicate.
Relative expression levels of miR-3148 and TLR7 were normal-
ized to the level of snRNA U6 and RPLP0, respectively, calculated
by the 22DDCt method and Log10 transformed. Association
between transcript levels of TLR7 and miR-3148 was evaluated
using linear regression test.
Flow cytometry
Four-color flow cytometry was performed to investigate
intracellular expression of TLR7 and TLR8 in PBMCs from
healthy EA and Asian individuals who were homozygous for
rs3853839 (7 pairs of G-allele vs. C-allele carriers in each gender
group). Freshly isolated PBMCs were incubated with 2% pooled
human serum to block nonspecific binding to Fcc receptors and
then incubated with peridinin chlorophyll protein (PerCP)-
conjugated anti-human CD3, allophycocyanin (APC)-conjugated
anti-human CD19 and phycoerythrin (PE)-conjugated or fluores-
cein isothiocyanate (FITC)-conjugated anti-human CD14 (Milte-
nyi Biotec) to identify T cell, B cell and monocyte subpopulations,
respectively. For intracellular staining, PBMCs were fixed in
Fixation buffer (R&D Systems) for 10 minutes at room temper-
ature, washed twice in Permeabilization/Wash buffer (R&D
Systems) and stained with PE-conjugated mouse anti-human
TLR7 mAb (R&D Systems) and FITC-conjugated mouse anti-
human TLR8 mAb (Imgenex) for 1 hour at room temperature.
Background fluorescence was assessed using appropriate isotype-
and fluorochrome-matched control antibodies. Cells were col-
lected and analyzed by FACSCalibur flow cytometer equipped
with the manufacturer’s software (CellQuest; BD Biosciences).
Student’s t test was used to compare protein levels of TLR7 or
TLR8 in PBMCs from individuals of different genotypes.
Plasmid construction and luciferase reporter assay
The fragment of TLR7 39-UTR bearing the G or C allele of
rs3853839 was amplified by PCR from genomic DNA of subjects
homozygous for the G or C allele using the following primers: 59-
TGTCTCGAGCCCTTCTTTGCAAAAC-39 (forward) and 59-
AGAGCGGCCGCTAGTTGGCTCCAGCAAT-39 (reverse).
The PCR products were inserted into the downstream of the
Renilla luciferase gene in the reporter vector psiCHECK-2
(Promega) by digestion using the restriction enzymes Not I and
Xho I. The psiCHECK-2 vector also contained a firefly luciferase
gene to serve as an internal transfection normalization control. All
constructs were sequenced to assure proper orientation and
authenticity in the vector.
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HEK-293 (human embryonic kidney cell line) and HL-60
(human leukemic cell line) cells were obtained from the American
Type Culture Collection (ATCC). HEK-293 cells were main-
tained in Dulbecco’s modified Eagle’s medium supplemented with
10% FBS, seeded on a 24-well plate at a concentration of 26105
cells/well, and transiently transfected using Lipofectamine 2000
(Invitrogen) with 1 mg of either rs3853839 G or C reporter
construct. HL-60 cells are predominantly a neutrophilic promy-
elocyte (precursor) and can be induced to differentiate to
neutrophil-like cells when grown in RPMI 1640 medium with
15% FBS plus 2 mM L-glutamine, 25 mM HEPES and 1.25%
DMSO [44]. Differentiated HL-60 cells seeded on 24-well plates
(26106 cells/well) were electroporated with 3 mg of report
construct on a nucleofector device (Amaxa). The luciferase activity
in total cell lysates was measured after 24 hours using a dual
luciferase reporter assay system (Promega). Renilla luciferase
activities were normalized to firefly luciferase activities. Each
transfection was performed in quadruplicates and triplicates for
HEK-293 and HL-60 cells respectively, and luciferase assays were
repeated four times.
MicroRNA hsa-miR-3148 and nontarget control (NC) mimics
were synthesized by Thermo Fisher Scientific. To test the effect of
miR-3148, HEK-293 cells plated in 96-well plates were transiently
cotransfected with 100 ng of each reporter construct (psiCHECK-
2 empty vector, rs3853839-G or -C allele constructs) and
increasing concentrations (1, 6, 12 and 48 nM) of miR-3148 or
nontarget control mimic using Lipofectamine 2000 reagent
(Invitrogen), and luminescence was measured 24 hours after
transfection. Each transfection was performed in quadruplicates
and repeated three times. Luciferase activity of reporter vectors
was compared using Student’s t test.
Assessment of allelic difference in RNA degradation rate
PBMCs isolated from EA healthy women with the GC genotype
of rs3853839 (n = 7) were cultured in the absence or presence of
5 mg/mL ActD for 0, 2, 4, 6 and 24 hours. Using real-time PCR,
we detected a decrease in total TLR7 mRNA levels over time with
ActD incubation, which confirmed the transcriptional inhibition
by ActD and allowed for detection of allelic differences in mRNA
degradation. The G/C allelic ratio in the cDNA and gDNA after
treatment of PBMCs with or without ActD were determined by
pyrosequencing and calculated using software PSQMA 2.1
(Biotage) as previously described [5]. The G/C allele ratio
obtained in TLR7 transcripts was normalized to that measured
from gDNA of the same sample. A paired t test was used to
compare the mean G/C allele ratio in TLR7 transcripts in PBMCs
treated with ActD or vehicle control at each time point.
Statistical analysis
Associations of SNPs with SLE were assessed in each ancestral
group under a logistic regression model adjusted for gender and
the first three principal components estimated using AIMs.
Conditional haplotype-based association tests were also performed
by adjusting for gender and the first three principal components.
The trans-ancestral meta-analysis was conducted on 40 genotyped
and 14 imputed SNPs that were shared by the three ancestries
with both a fixed and random-effects model. Homogeneity of odds
ratios was evaluated using Cochrane’s Q test. For each SNP, if the
Cochran’s Q test showed no evidence of genetic heterogeneity
(P.0.05), a fixed-effects model was implemented; otherwise, a
random-effects model was used. The Bonferroni corrected P-value
threshold was adjusted to P,9.161024 on the basis of the
maximum number of tests across all populations (55 independent
variants with r2,0.8). All analyses described above were
performed using PLINK v1.07. Pairwised LD values shown in
Figure 1 and Figure S1 were calculated using Haploview 4.2.
Other data were analyzed using GraphPad Prism 4.0 software. A
P value,0.05 was considered to be statistically significant.
Supporting Information
Figure S1 Conditional haplotype-based association tests among
seven SNPs within TLR7-TLR8 region that show consistent
association with SLE (P,0.05) in all three ancestral groups. (A)
Trans-ancestry meta-analysis of 40 genotyped SNPs (circles) and
14 imputed SNPs (triangles) that are shared by the three ancestries
using fixed and random model, respectively. The rectangle
indicates the seven SNPs that show significant and consistent
association with SLE in all three ancestral groups. Arrows identify
the two strongest SNPs in the meta-analysis. The dashed line
represents the significance level of 561028. (B, C, D) Pairwised
LD values (r2) of the seven SLE-associated SNPs, their allelic P
value and P value after conditioning on the SNP shown as ‘‘–’’ are
depicted in EA, AA and HS ancestry, respectively. ND represents
that these two SNPs are non-distinguishable in the conditional test.
(TIF)
Figure S2 Representative dot plots and quantification of
CD3+TLR7+ T cells, CD19+TLR7+ B cells and CD14+TLR7+
monocytes in PBMCs from healthy women (A, B) and men (C, D)
carrying G or C allele of rs3853839 (n = 7 pairs GG or G vs. CC
or C in each gender group). Numbers in upper quadrants indicate
mean percentages of double positive cells in PBMCs.
(TIF)
Figure S3 Fluorescence-activated cell sorter (FACS) analysis of
TLR8 staining. (A) FACS histograms show the log MFI values
plotted against the cell counts for PBMCs in individuals carrying
either G or C allele of rs3853839. Results are from 1
representative pair (GG or G vs. CC or C) of 7 in each gender
group. (B) MFI of TLR8 expression in PBMCs is graphically
depicted. Each symbol represents an individual and horizontal
lines indicate mean 6 SEM values. (C, D) Quantification of
CD3+TLR8+ T cells, CD19+TLR8+ B cells and CD14+TLR8+
monocytes in PBMCs from healthy women and men carrying G or
C allele of rs3853839, respectively.
(TIF)
Figure S4 Higher G/C allele ratio in cDNAs than in gDNAs
from PBMCs of seven healthy EA women heterozygous for
rs3853839.
(TIF)
Figure S5 The kinetics of TLR7 mRNA levels in PBMCs after
incubation with or without actinomycin D (ActD). PBMCs from
heterozygous individuals (n = 7) were cultured in the absence or
presence of 5 mg/mL actinomycin D for the indicated time, and
then TLR7 mRNA levels were measured by RT-PCR normalized
to RPLP0. Data are presented as mean 6 SEM at each time point
and representative of two independent experiments with seven
donors.
(TIF)
Table S1 Allelic associations of TLR7/8 SNPs with SLE in
European Americans (EA), African Americans (AA) and Amerin-
dian/Hispanics (HS). Position of each SNP is based on GRch37/
hg19. Seven SNPs that showed consistent association with SLE
(P,0.05) in all 3 ancestral groups are highlighted in gray. The
meta-analysis was performed with both fixed and random-effects
model. If the Cochran’s Q statistic showed no evidence of genetic
heterogeneity (P.0.05), the P value and OR from a fixed effect
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model was applied. Otherwise, a random effect model was used.
The finally applied meta P value and OR for each SNP are
highlighted in bold. Abbreviation: G, genotype; I, imputed; OR,
odds ratio; –, missing data.
(DOC)
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